dihydroergotamine has been researched along with Analgesic Overuse Headache in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patterson-Gentile, C; Szperka, CL | 1 |
| Diener, HC; Tfelt-Hansen, PC | 1 |
| Gelfand, AA; Goadsby, PJ | 1 |
| Dodick, D; Rapoport, A; Saper, JR; Silberstein, S | 1 |
4 review(s) available for dihydroergotamine and Analgesic Overuse Headache
| Article | Year |
|---|---|
The Changing Landscape of Pediatric Migraine Therapy: A Review.
Topics: Adolescent; Adrenergic beta-Antagonists; Amitriptyline; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Calcium Channel Blockers; Child; Cognitive Behavioral Therapy; Dihydroergotamine; Dopamine Antagonists; Fluid Therapy; Glucocorticoids; Headache Disorders, Secondary; Humans; Magnesium; Migraine Disorders; Nerve Block; Topiramate; Tryptamines; Valproic Acid | 2018 |
Use of dihydroergotamine (DHE) should be restricted to no more than twice a week.
Topics: Analgesics, Non-Narcotic; Dihydroergotamine; Headache Disorders, Secondary; Humans; Migraine Disorders | 2014 |
Medication overuse in children and adolescents.
Topics: Adrenal Cortex Hormones; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Dihydroergotamine; Drug Administration Schedule; Headache Disorders, Primary; Headache Disorders, Secondary; Humans; Naproxen; Prevalence; Prognosis; Treatment Outcome | 2014 |
DHE in the pharmacotherapy of migraine: potential for a larger role.
Topics: Analgesics, Non-Narcotic; Dihydroergotamine; Headache Disorders, Secondary; Humans; Migraine Disorders; Prevalence | 2006 |